Keyphrases
Dengue
100%
EDIII
100%
Immunogen
100%
Glycoprotein
57%
Subunit Vaccine
42%
Flavivirus
28%
Broadly Neutralizing Antibodies
28%
Primary Infection
28%
Epitope
28%
BNAbs
28%
Presentation Format
14%
Shock Syndrome
14%
Dengue Disease
14%
Multiple Serotypes
14%
Serum Transfer
14%
Immunogen Design
14%
Severe Dengue
14%
Design Strategy
14%
Hyperendemic
14%
Chimeric Vaccine
14%
Dengue Virus
14%
Vaccine Immunogen
14%
Neutralization Epitope
14%
Global Concern
14%
Prototypic
14%
Immunogenicity
14%
Asymptomatic Infection
14%
Non-productive
14%
Conformational Integrity
14%
Non-neutralizing Antibodies
14%
Binding Affinity
14%
Secondary Infection
14%
Amino Acid Diversity
14%
Type-specific
14%
In Vitro Characterization
14%
Folding Stability
14%
Febrile Illness
14%
Protein Engineering
14%
Human Infection
14%
Phage Display
14%
Immunodominant Region
14%
Phage Display Library
14%
Monovalent Cations
14%
Live Attenuated
14%
Engineering Approach
14%
Protective Immunity
14%
Heterotypic
14%
Modified-live Virus Vaccine
14%
Antibody-dependent Enhancement
14%
Long-term Immunity
14%
Nave
14%
Display Platform
14%
Structure-based Design
14%
Biochemical Properties
14%
Challenge Test
14%
Neutralizing Antibodies
14%
Immunology and Microbiology
Dengue Fever
100%
Infection
100%
Serotype
71%
Glycoprotein
57%
Dengue Virus
57%
Neutralizing Antibody
42%
Subunit Vaccine
42%
Epitope
42%
Flavivirus
28%
Virus Vaccine
14%
Binding Affinity
14%
Dengue Virus 1
14%
Bacteriophage
14%
Phage Display
14%
Neutralization
14%
Virus Attenuation
14%
Protein Engineering
14%
Antibody Response
14%
Antibody-Dependent Enhancement
14%
Immunogenicity
14%
Amino Acid
14%
In Vitro
14%
Biochemistry, Genetics and Molecular Biology
Serotype
100%
Dengue Virus
80%
Glycoprotein
80%
Neutralizing Antibody
60%
Flavivirus
40%
Antibody Dependent Enhancement
20%
Dengue Virus 1
20%
Phage Display
20%
Virus Attenuation
20%
Immunogenicity
20%
Amino Acids
20%
Protein Engineering
20%
Antibody Response
20%
Binding Affinity
20%
Bacteriophage
20%